Pradaxa Lawsuits Move Forward, with Issuance of New Order Pertaining to Second Bellwether Trial in Federal Pradaxa Bleeding Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating Pradaxa lawsuits on behalf of patients who suffered uncontrollable internal bleeding, allegedly due to the blood thinner.

Free Case Review
Our Firm receives Pradaxa lawsuit inquiries on a regular basis from individuals who allegedly suffered uncontrollable internal bleeding due to their use of the blood thinning medication.

The federal judge overseeing thousands of Pradaxa lawsuits ( pending in the U.S. District Court, Southern District of Illinois has issued a new Pretrial Order pertaining to the proceeding’s second bellwether trial. Among other things, the Order directs that depositions be completed by October 17, 2014. Jury selection will begin on December 1, 2014, with opening statements to begin once selection has concluded. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“Our Firm receives Pradaxa lawsuit inquiries on a regular basis from individuals who allegedly suffered uncontrollable internal bleeding due to their use of the blood thinning medication. We look forward to the commencement of bellwether trials this year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to individuals who allegedly experienced serious Pradaxa bleeding side effects.

Pradaxa Bleeding Allegations
Court records indicate that at least 2,460 Pradaxa lawsuits have been filed in the Southern District of Illinois on behalf of individuals who allegedly experienced cerebral hemorrhage, gastrointestinal bleeding, and other serious episodes of internal bleeding due to their use of the medication. Among other things, these lawsuits claim that Boehringer Ingelheim did not provide doctors and patients with adequate warnings regarding the lack of an antidote to reverse potential Pradaxa bleeding side effects.

According to court documents, the first bellwether trial in the Pradaxa litigation is scheduled to begin on September 8, 2014. Bellwether trials are an important milestone in large, complex litigations, as they may provide important insight into how other juries might decide similar claims.

Pradaxa was first approved by the U.S. Food & Drug Administration (FDA) in 2010, and was touted as an improvement over warfarin. However, Pradaxa lawsuits point out that the internal bleeding that sometimes accompanies warfarin use can be stopped via the administration of vitamin K. In February, a segment aired by 7 Action News in Detroit revealed that the FDA has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. Many of these cases detailed episodes of uncontrollable internal bleeding. *

Pradaxa patients who allegedly suffered from the drug’s bleeding side effects may be entitled to compensation. Learn more about Pradaxa lawsuits at Bernstein Liebhard LLP’s website. Please call 800-511-5092 to schedule a free, no obligation case review.

*, 7 Action News, February 25, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website